Sarah Gooding

7PUBLICATIONS
76CO-AUTHORS
ElectrometallurgyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityHaematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 12, 2026
Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

|May 08, 2026
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

|Dec 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.

Clement Twumasi, Sally Moore, Ross Sadler

|Nov 09, 2022
Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies.

Abdullah O Khan, Antonio Rodriguez-Romera, Jasmeet S Reyat

|Jul 19, 2022
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.

Sarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun

|May 06, 2022
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.

Parvathi Sudha, Aarif Ahsan, Cody Ashby

Pageof 2

Frequent Collaborators

2 joint publications

Karthik Ramasamy

2 joint publications

Anita Krithivas Gandhi

2 joint publications

Anjan Thakurta

2 joint publications

Thomas A Milne